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cancer cell has the ability to invade host 
stroma and to metastasize.  Metastasis refers 
to the ability of cancer cells to invade stroma and to 
generate secondary tumors at sites distant from the 
primary tumor.  It is well known that the spread of 
tumors can be enhanced not only by cancer cells but 
also by interstitial cells.  It is becoming clear that 
various cytokines,  which are produced from cancer 
tissue including interstitial cells,  are associated with 
invasion and metastasis [1,  2].  Cytokines are con-
sidered to form a cytokine network,  either autocrine 
or paracrine,  and to be involved in the system of 
invasion and metastasis through receptors expressed 
on cancer cells.  It has been found that interleukin-6 
(IL-6) has multiple biological activities [3ﾝ6].  We 
considered the possibility of stimulating cancer cell 
growth by IL-6,  and investigated IL-6’s possible role 
in predicting the spread of tumors,  including invasion 
and metastasis.  We have already reported a signiﬁ -
cant correlation between serum IL-6 values and both 
lymph node and hepatic metastasis from colorectal 
cancer,  and we have elucidated the role of IL-6 as a 
prognostic factor [7].  The purpose of the present 
study was to clarify IL-6’s diagnostic signiﬁ cance for 
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We investigated the diagnostic signiﬁ cance of IL-6 for lymph node metastasis and/or hepatic metasta-
sis from colorectal cancer in 65 patients and evaluated the contributions of 8 factors (IL-6,  HGF,  IL-1
ｹ,  TNF-ｸ,  TGF-ｹ1,  ELAM-1,  ICAM-1,  VCAM-1) toward Dukes’s classiﬁ cation of 53 patients.  We 
also examined IL-6 expression in tumor tissue.  From the receiver operating characteristic (ROC) 
curve analysis,  an optimal cutoﬀ  value of 5.8 pg/ml was determined to classify lymph node and/or 
hepatic metastasis,  and that of 6.3 pg/ml was determined to classify hepatic metastasis.  These values 
indicated sensitivities of 55.0ｵ and 71.4ｵ,  and speciﬁ cities of 100ｵ and 88.6ｵ,  respectively.  IL-6, 
HGF,  and ELAM-1 were very useful for distinguishing among Dukes’s A/B group,  C group,  and D 
group.  In all cases with high IL-6 values (more than 25.0 pg/ml),  immunohistochemical staining was 
positive for IL-6 in the cytoplasm of cancer cells.  IL-6 is strongly suspected to be involved in lymph 
node and/or hepatic metastasis by promoting it through HGF,  and serum IL-6 value (pg/ml) would 
be useful diagnostically to estimate whether or not there is a high risk of lymph node and/or hepatic 
metastasis.
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lymph node metastasis and/or hepatic metastasis and 
to analyze the serum levels of IL-6,  IL-6-related 
cytokines,  and adhesion molecules to distinguish 
patients with colorectal cancer according to Dukes’s 
classiﬁ cation.
Patients and Methods
　　Sixty-ﬁ ve patients with colorectal cancer diag-
nosed histopathologically without pre-treatment,  and 
who underwent surgery at our department between 
January 1998 and August 2002,  were enrolled in this 
study.  The patients consisted of 46 men and 19 
women (mean age 65.5 y/o,  range 26ﾝ89 y/o). 
Twenty-one patients were considered to have hepatic 
metastasis clinically (Dukes’s D),  8 patients with 
Dukes’s A,  17 with Dukes’s B,  and 19 with Dukes’s 
C (Table 1).
　　Variables.　 In the 65 patients with colorectal 
cancer,  we statistically assessed the preoperative 
serum values of IL-6 (pg/ml) to be of diagnostic sig-
niﬁ cance for 1) lymph node metastasis and/or hepatic 
metastasis,  and 2) hepatic metastasis.  3) We ana-
lyzed the contributions of IL-6,  IL-6-related cyto-
kines (hepatocyte growth factor (HGF) (ng/ml), 
interleukin-1ｹ (IL-1ｹ) (pg/ml),  tumor necrosis fac-
tor-ｸ (TNF-ｸ) (pg/ml),  transforming growth factor-
ｹ1 (TGF-ｹ1) (ng/ml)),  and adhesion molecules (inter-
cellular adhesion molecule-1 (ICAM-1) (ng/ml),  vas-
cular-cellular adhesion molecule-1 (VCAM-1) (ng/ml), 
and endothelial cell leukocyte adhesion molecule-1 
(ELAM-1) (ng/ml)) to apply Dukes’s classiﬁ cation to 
53 patients.  4) We also examined the expression of 
IL-6 in tumor tissue in 6 cases with high serum lev-
els (more than 25.0 pg/ml) and in 4 cases with low 
serum levels (less than 2.0 pg/ml) of IL-6.
　　Histological ﬁ ndings were described according to 
the Japanese Society for Cancer of the Colon and 
Rectum (7 th edition) [8].
　　Assay of serum cytokine value.　 The serum 
value of IL-6 was measured by chemiluminescent 
enzyme immunoassay (CLEIA) using a commercial 
kit (Fujirebio Inc.,  Tokyo,  Japan).  Serum values of 
several cytokines were measured by enzyme-linked 
immunosorbent assay (ELISA) by commercially avail-
able methods : HGF (Otsuka Pharmaceutical Co., 
Ltd.,  Tokyo,  Japan),  IL-1ｹ (Biosource Europa S.A., 
Camarillo,  CA,  USA),  TNF-ｸ (Japan Immuno-
research Laboratories Co.,  Ltd.,  Gunma,  Japan), 
and TGF-ｹ1 (R&D Systems Inc.,  Minneapolis,  MN, 
USA).
　　Immunohistochemical staining.　 IL-6 was 
detected by anti-human IL-6 monoclonal antibody 
(Cosmo Bio Co.,  Ltd.,  Tokyo,  Japan).  Immunohisto-
chemical staining was performed using a labeled 
streptavidin-biotin (LSAB) kit (Dako Cytomation 
Tokyo Inc.,  Tokyo,  Japan).  IL-6 immunostaining was 
judged to be positive when more than 10ｵ of cancer 
cells were detected by immunostaining in the cyto-
plasm.
　　Statistical analysis.　 Receiver operating char-
acteristics (ROC) analysis was used to calculate cut-
oﬀ  values to determine the probability that most ade-
quately classiﬁ ed lymph node and/or hepatic metasta-
sis.  The ROC curves were traced using ROCKIT 
software (Kurt Rossmann Laboratories,  Chicago, 
IL,  USA),  and the cutoﬀ  point,  sensitivity,  and 
speciﬁ city were measured.  We analyzed 8 factors 
(IL-6,  4 IL-6-related cytokines,  and 3 adhesion mol-
ecules) to distinguish patients according to Dukes’s 
classiﬁ cation by canonical discriminate analysis, 
which was conducted in order to distinguish among a 
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Table 1　　Patients’ characteristics
Variable Number of patients
Total patients 65
Age (years)
　Median 65.5
　Range 26ﾝ89
Gender (%)
　Male 46 (70.8)
　Female 19 (29.2)
Location (%)
　Cecum 7 (10.8)
　Ascending 9 (13.8)
　Transverse 8 (12.3)
　Descending 1 ( 1.5)
　Sigmoid 14 (21.5)
　Rectum 26 (40.0)
Dukes’ classiﬁ cation (%)
　A 8 (12.3)
　B 17 (26.2)
　C 19 (29.2)
　　n1 (＋) 11 (16.9)
　　n2 (＋) 5 ( 7.7)
　　n3 (＋) 3 ( 4.6)
　D (H’ (＋)) 21 (32.3)
group of samples from potentially diﬀ erent popula-
tions.  This technique creates canonical varieties 
from the original variables containing the relevant 
information for discrimination.  Canonical discrimi-
nate analysis was calculated using the Statistical 
Analysis System (SAS) from SAS Institute (Cary, 
NC,  USA).
Results
　　1.  The classiﬁ cation capability of the model from 
the ROC curve analysis was 0.718 (cutoﬀ  
point : SE : 0.063,  95ｵ CI : 0.593ﾝ0.823),  and this 
cutoﬀ  point had a sensitivity of 55.0ｵ (22 of 40 
cases),  a speciﬁ city of 100ｵ (25 of 25 cases),  a pos-
itive predictive value of 100ｵ (22 of 22 cases),  and 
a negative predictive value of 58.1ｵ (25 of 43 cases) 
for determining the absence or presence of lymph 
node metastasis and/or hepatic metastasis.  An opti-
mal cutoﬀ  value of 5.8 pg/ml was determined to clas-
sify them (Fig.  1).
　　2.  The classiﬁ cation capability of the model from 
the ROC curve analysis was 0.819 (cutoﬀ  
point : SE : 0.061,  95ｵ CI : 0.704ﾝ0.904),  and this 
cutoﬀ  point had a sensitivity of 71.4ｵ (15 of 21 
cases),  a speciﬁ city of 88.6ｵ (39 of 44 cases),  a 
positive predictive value of 75.0ｵ (15 of 20 cases), 
and a negative predictive value of 86.7ｵ (39 of 45 
cases) for determining the absence or presence of 
hepatic metastasis.  An optimal cutoﬀ  value of 6.3 pg/
ml was determined to classify them (Fig.  2).
　　3.  Dukes’s D group could be distinguished from 
the A,  B,  and C groups by the ﬁ rst canonical axis 
(a-a’).  HGF (0.77) contributed primarily and IL-6 
(0.46) contributed secondarily to obtain the ﬁ rst 
canonical axis.  Then,  Dukes’s C group could be dis-
tinguished from the A and B groups by the second 
canonical axis (b-b’),  and the contribution of ELAM-1 
(1.01) was strong enough to obtain a second canonical 
axis.  However,  these 8 factors did not contribute 
enough to distinguish between Dukes’s A and B 
groups (Fig.  3).
　　4.  In all 6 cases with high serum levels (more 
than 25.0 pg/ml) of IL-6,  immunohistochemical stain-
ing showed positive ﬁ ndings for IL-6 in the cytoplasm 
of cancer cells.  On the other hand,  there was no evi-
dence of positive ﬁ ndings for IL-6 in the 4 cases with 
low serum levels (less than 2.0 pg/ml) of IL-6.
Discussion
　　In 1986,  the nucleotide deduced amino acid 
sequences of cloned human IL-6 cDNA were puriﬁ ed. 
Human IL-6 consists of 212 amino acids,  including a 
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Fig. 1　　ROC curve traced using ROCKIT software for lymph 
node and/or hepatic metastasis by the preoperative serum IL-6 
values.
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Fig. 2　　ROC curve traced using ROCKIT software for hepatic 
metastasis by the preoperative serum IL-6 values.
hydrophobic signal sequence of 28 amino acids [9ﾝ
11].  On the other hand,  the receptor system of IL-6 
consists of an 80 kD glucoprotein (IL-6R) and a 
130 kD glucoprotein (gp 130),  and signals are trans-
ferred into cells by IL-6 combined with IL-6R on the 
cell membrane [12].  We considered the possibility 
of stimulating cancer cell growth by IL-6,  and inves-
tigated the possible role of IL-6 in predicting the 
spread of tumors,  including invasion and metastasis. 
Actually,  we have already reported a signiﬁ cant rela-
tionship (r ＝ 0.43074,  p ＜ 0.01) between serum IL-6 
values and Dukes’s classiﬁ cation,  and have also 
showed signiﬁ cant correlations between IL-6 and 
both lymph node metastasis (r ＝ 0.46864, p ＜ 0.01) 
and hepatic metastasis (Fisher prob ＝ 0.000001, 
p ＜ 0.01) [7].
　　Cancer metastasis is a complex process involving 
coordinated cellular responses of both cancer cells 
and normal cells.  Metastasis involves several 
steps : 1) invasion of the stroma,  2) intravasation of 
the blood vessel,  3) circulation in the blood,  4) lodg-
ing and adhesion in target capillaries,  5) extravasa-
tion from the blood vessels,  and 6) proliferation of 
secondary tumors [13].  IL-6 is thought to be 
involved in steps 1,  2,  and 3.
　　As proof of the mechanism of IL-6 involved in 
steps 1,  2,  and 3,  Tamm et al.  showed that IL-6 
increases the motogenic activity of cancer cells by 
the autocrine pathway (that is,  IL-6 secreted from 
the cancer cells combines with IL-6R,  which is 
expressed on the surface of cancer cells ; together, 
IL-6 and IL-6R act on cancer cells directly.) [14]. 
Subsequent research showed clearly that a paracrine 
pathway is involved in the eﬀ ects of HGF and IL-6 
on the invasion and metastasis of cancer cells [15ﾝ
17].  When IL-6 produced by cancer cells stimulates 
interstitial cells to secrete HGF,  HGF combines 
with the HGF receptor (c-Met) expressed on cancer 
cells.  HGF raises the motogenic activity of these 
cells,  and it is thought that the cancer cells move to 
the metastasis site [18,  19].  Actually,  there was a 
signiﬁ cant relationship (r ＝ 0.53226,  p ＜ 0.01) 
between IL-6 and HGF in our research [7],  and 
IL-6 may act through HGF on cancer cells by the 
promotion and acceleration of developing invasion 
and lymph node metastasis and/or hepatic metastasis.
　　It has been reported that ICAM-1,  VCAM-1,  and 
ELAM-1 are expressed on endothelial cells by proin-
ﬂ ammatory cytokines such as IL-1ｹ and TNF-ｸ, 
which are located upstream of IL-6 [20,  21] and 
which,  combined with IL-6,  promote the adhesion of 
cancer cells and endothelial cells [22].  However, 
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Fig. 3　　Fifty-three patients are distinguished according to Dukes’s classiﬁ cation by canonical discriminant analysis.  Dukes’s D group 
can be distinguished from Dukes’s A,  B,  and C groups by the ﬁ rst canonical axis (a-a’).  Dukes’s C group can be distinguished from 
Dukes’s A and B groups by the second canonical axis (b-b’).
IL-6 did not correlate signiﬁ cantly with IL-1ｹ 
(r ＝ 0.0517,  NS) or TNF-ｸ (r ＝ 0.12136,  NS) in our 
research [7].
　　Although speciﬁ c IL-6 immunostaining was 
observed in the cytoplasm of cancer cells in all 6 
patients with high IL-6 values (more than 25.0 pg/
ml),  IL-6 immunostaining was not shown in 4 patients 
with low IL-6 values (less than 2.0 pg/ml).  This 
strongly suggested that the high serum value of IL-6 
reﬂ ects IL-6 secretion by cancer cells.  However,  it 
remains unclear what up-regulates IL-6 production in 
cancer cells.  Experimental studies have recently 
demonstrated that in vitro treatment of Kupﬀ er cells 
with carcinoembryonic antigen (CEA) induces expres-
sion of cytokines such as IL-1ｸ,  IL-1ｹ,  IL-6,  and 
TNF-ｸ [22].  In addition,  the injection of CEA into 
mice results in a signiﬁ cant dose-dependent IL-6 
response [23].  Furthermore,  Belluco et al.  reported 
that the preoperative serum concentration of IL-6 
was associated with CEA in 208 patients with 
colorectal cancer [24].  These data suggest that 
CEA induces the systemic production of IL-6.  In 
fact,  a signiﬁ cant relationship between IL-6 and 
CEA was found in the present study (data not 
shown ; Spearman rank correlation ＝ 0.59726, 
p ＜ 0.01).
　　Because IL-6 is aﬀ ected by various clinical condi-
tions,  such as sepsis,  trauma,  surgery,  inﬂ amma-
tion,  and other forms of chronic stress,  its serum 
level may reﬂ ect a lot of indeﬁ nite bias.  It is there-
fore not necessarily suitable as a screening modality 
to rule out malignancy.  Our results suggest that the 
clinical signiﬁ cance of IL-6 is limited to evaluating 
the spread of colorectal cancer,  and that IL-6 should 
be used as a tumor marker for lymph node metastasis 
and/or hepatic metastasis.  In general,  ROC analysis 
can be employed to assess performance in any 
2-group classiﬁ cation task.  The ROC curve repre-
sents the relationship between ‘true positive fraction’ 
(TPF) and the ‘false positive fraction’ (FPF).  In the 
terminology of medical diagnosis,  TPF is equivalent 
to ‘sensitivity’,  whereas FPF is equivalent to 1-‘spec-
iﬁ city’.  The ROC curve displays the trade-oﬀ  
between sensitivity and speciﬁ city that a diagnostic 
test allows as the cutoﬀ  between nominally negative 
and nominally positive test results (that is,  the 
threshold of abnormality) varies [25,  26].  Actually, 
when the optimal cutoﬀ  values of IL-6 were set at 
5.8 pg/ml with regard to the diagnostic signiﬁ cance 
of serum IL-6 values for lymph node metastasis and/
or hepatic metastasis,  and to 6.3 pg/ml for hepatic 
metastasis,  the sensitivity values were 55.0ｵ and 
71.4ｵ and the speciﬁ city values were 100ｵ and 
88.6ｵ,  respectively.  Although it cannot be said that 
the sensitivity is high enough,  the speciﬁ city is high 
and is not inferior to those for other tumor markers, 
such as CEA and carbohydrate antigen (CA) 19ﾝ9 
[27].  Therefore,  serum IL-6 may be valuable as a 
prognostic factor for survival,  and it is recommended 
for the preoperative prediction of disease stage. 
However,  the inﬂ uence of IL-6,  as well as the inﬂ u-
ences of related factors,  were not clear enough to 
allow us to evaluate tumor invasion from the results 
of canonical discriminate analysis.  In patients with 
colorectal cancer who showed high levels of 
C-reactive protein (CRP) before surgery (in this 
research,  17 examples (81.0ｵ) showed a rise of 
CRP among 21 IL-6 high-value patients) [28,  29], 
examination of serum IL-6 level and IL-6 expression 
in cancer cells would be diagnostically useful for 
estimating whether or not there is a high risk of 
lymph node metastasis and/or hepatic metastasis.
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